Investigation of Blood Pressure Variability and Analysis of Risk Factors for Hypertension Using Ambulatory Blood Pressure Monitoring in Patients Receiving Angiogenesis Inhibitors

Investigation of Blood Pressure Variability and Analysis of Risk Factors for Hypertension Using Ambulatory Blood Pressure Monitoring in Patients Receiving Angiogenesis Inhibitors - BLOSSOM study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052201

Enrollment

100

Registered

2023-09-15

Start date

2023-06-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients 20 years of age or older who are scheduled to receive chemotherapy including one of the following angiogenesis inhibitors (bevacizumab, ramucirumab, aflibercept beta, regorafenib, lenvatinib, sunitinib, sorafenib, or vandetanib)

Exclusion criteria

Exclusion criteria: 1)Patients with a history of prior administration of angiogenesis inhibitors 2)Patients who cannot have 24-hour free blood pressure monitoring 3)Patients with performance status is more than 3 4)Patients on dialysis therapy 5)Patients deemed inappropriate for the study by the investigator

Design outcomes

Primary

Measure	Time frame
Changes in blood pressure trends with 24-hour free blood pressure measurement	—

Secondary

Measure	Time frame
Major adverse cardiovascular events (ventricular/supraventricular arrhythmia, heart failure, heart block, sudden cardiac death, other cardiovascular events)	—

Countries

Japan

Contacts

Public ContactAtsushi Kawanobe

National cancer center hospital east Department of Pharmacy

akawanob@east.ncc.go.jp0471331111

Outcome results